Event Detail

Since the introduction of ICH Informed Consent in 1997, the Japanese pharmaceutical sector has undergone a significant realignment and consolidation. Foreign makers have increased their market shares year-on-year for nearly two decades as their Japanese counterparts have consolidated and increasingly expanded into global markets.



- Is the Japanese pharmaceutical industry posed for further consolidation?

- Who are the winners in globalization?

- Who's winning in Japan?

- How is super aging in Japan and the region impacting pharma trends?

- What is the future of biological treatments?

- Where is the growth coming from?

- With the U.S. and EU in a period of slow growth while China and other emerging economies grow at double digit rates, how is the Japan market viewed by Big Pharma?

- What are the key trends today and tomorrow?



With over twenty years of experience in the field, Alan Thomas has become one of the leading experts in pharmaceutical marketing in Japan. Alan will provide commentary based on the most recent IMS data on the significant ongoing trends in the pharmaceutical sector and key market dynamics in Japan and globally.



If your company is involved or interested in the pharmaceutical industry and if you are seeking a better understanding of key global trends and key market insights including Gemba dynamics in Japan, this is an event you cannot afford to miss.



Please join us and be sure to bring your questions.



Venue: Tokyo American Club, Manhattan (B2)



Note: This event is ON THE RECORD





Healthcare Committee

William Bishop, Chair

R. Byron Sigel, Vice-Chair



Pharmaceuticals Subcommittee

Ira Wolf, Chair



Medical Devices and Diagnostics Subcommittee

William Bishop, Chair